SpeeDx announces Series A round
Executive Summary
SpeeDx Pty. Ltd. raised an undisclosed sum in its Series A financing to new backer Northpond Ventures, which adds a board member. The company’s ResistancePlus MG can diagnose Mycoplasma genitalium and genetic markers linked to macrolide antibiotic resistance. The diagnostic is currently in the clinic and an FDA filing is expected later this year. The test will soon be available in Europe on the Cepheid GeneXpert system. SpeeDx also has a ResistancePlus test for detecting gonorrhea infection and markers linked to susceptibility to ciprofloxacin.
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice